Comparative Pharmacology
Head-to-head clinical analysis: IOFLUPANE I 123 versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOFLUPANE I 123 versus ULTRATAG.
IOFLUPANE I-123 vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ioflupane I-123 is a radiopharmaceutical that binds with high affinity to the dopamine transporter (DAT) in the striatum. It allows visualization of presynaptic dopaminergic neurons via single-photon emission computed tomography (SPECT) imaging.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
Intravenous: 148-185 MBq (4-5 mCi) administered as a single IV bolus injection over 20-30 seconds, followed by saline flush.
NOT FOUND
None Documented
None Documented
Terminal elimination half-life of ioflupane I-123 is approximately 25-30 hours. This prolonged half-life allows for imaging up to 6-8 hours post-injection with sustained target-to-background ratio, but requires consideration for radiation safety.
Clinical Note
moderateIoflupane I-123 + Methylphenidate
"Ioflupane I-123 may decrease effectiveness of Methylphenidate as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Venlafaxine
"Ioflupane I-123 may decrease effectiveness of Venlafaxine as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Nefazodone
"Ioflupane I-123 may decrease effectiveness of Nefazodone as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Fluvoxamine
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Primarily renal; about 60% of administered radioactivity excreted in urine within 24 hours, with 38% as unchanged ioflupane and 22% as metabolites. Fecal excretion accounts for approximately 14% over 48 hours. Additional elimination via biliary route is minimal.
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical
"Ioflupane I-123 may decrease effectiveness of Fluvoxamine as a diagnostic agent."